GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Symbiotec Pharmalab Ltd

Symbiotec Pharmalab Q2 FY27 Net Profit Rs. 517.18 Million; Revenue Rs. 2,799.28 Million

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 05 Nov 2026, 07:59 PM IST  ·  BSE ID: 3f657b14-ef00-41a5-8c03-e92e800ed588
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its Q2 FY27 financial results, reporting Rs. 517.18 Million in profit and Rs. 2,799.28 Million in revenue.
🤖 AI Summary
  • Symbiotec Pharmalab reported Q2 FY27 consolidated Net Profit of Rs. 517.18 Million.
  • Consolidated Revenue from operations for Q2 FY27 stood at Rs. 2,799.28 Million.
  • Total comprehensive income for Q2 FY27 was Rs. 524.05 Million.
  • The company completed its Initial Public Offering (IPO) during Q2 FY27, listing on September 1, 2026.
  • Paid-up equity share capital increased to Rs. 128.51 Million from Rs. 125.47 Million post IPO.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (Q2 FY27)
Rs. 2,799.28 Million
43.19%
Net Profit for the period/year (Q2 FY27)
Rs. 517.18 Million
169.13%
Basic EPS (Q2 FY27)
Rs. 8.20
137.68%
Total assets (as of Sep 30, 2026)
Rs. 20,439.15 Million
Paid-up equity share capital (as of Sep 30, 2026)
Rs. 128.51 Million
🏢 How This Affects the Company
💰
Financial Impact
The increase in paid-up equity share capital from Rs. 125.47 Million to Rs. 128.51 Million reflects the equity infusion from the IPO. Total assets increased to Rs. 20,439.15 Million as of September 30, 2026, from Rs. 17,807.92 Million as of March 31, 2026.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders of Symbiotec Pharmalab are affected by the company's financial performance, with reported Net Profit of Rs. 517.18 Million and basic EPS of Rs. 8.20 for Q2 FY27.
🔍
Management Signal
The approval of unaudited financial results and the completion of the IPO signal management's focus on capital market engagement and ongoing business operations.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check for sustained revenue and profit growth.
Updates on IPO proceeds utilization — monitor application of Rs. 1,420.25 Million.
Future board meetings — look for any further capital allocation decisions.
MEDIUM RISK The company recently completed its IPO (September 2026), indicating a limited public track record as a listed entity.
💡 Investor Takeaway
Symbiotec Pharmalab reported Q2 FY27 consolidated Net Profit of Rs. 517.18 Million, a 169.13% increase from Rs. 192.18 Million in Q2 FY26. Revenue from operations rose to Rs. 2,799.28 Million, up 43.19% from Rs. 1,955.15 Million in Q2 FY26. The company completed its IPO during the quarter, leading to a listing on September 1, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 Net Profit increased to Rs. 517.18 Million compared to Rs. 192.18 Million in Q2 FY26 (September 30, 2025).
  • Q2 FY27 Revenue from operations grew to Rs. 2,799.28 Million from Rs. 1,955.15 Million in Q2 FY26 (September 30, 2025).

⚠️ Concerns

  • Deferred Tax Charge/(Credit) shifted from a credit of Rs. (2.54) Million in Q2 FY26 to a charge of Rs. (46.16) Million in Q2 FY27.
  • Non-current financial liabilities (borrowings) significantly increased to Rs. 1,622.28 Million as of September 30, 2026, from Rs. 684.13 Million as of March 31, 2026.
📅 Company Track Record
Symbiotec Pharmalab completed its Initial Public Offering (IPO) during Q2 FY27, with equity shares listed on NSE and BSE on September 1, 2026. This IPO increased the paid-up equity share capital from Rs. 125.47 Million to Rs. 128.51 Million. The net proceeds from the fresh issue totaled Rs. 1,420.25 Million.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Symbiotec Pharmalab's consolidated Net Profit in Q2 FY27?
Symbiotec Pharmalab reported a consolidated Net Profit of Rs. 517.18 Million for the quarter ended September 30, 2026 (Q2 FY27).
What was Symbiotec Pharmalab's Revenue from operations in Q2 FY27?
The Revenue from operations for Symbiotec Pharmalab in Q2 FY27 was Rs. 2,799.28 Million.
When did Symbiotec Pharmalab's IPO shares list on exchanges?
The equity shares of Symbiotec Pharmalab were listed on National Stock Exchange of India Limited and BSE Limited on September 1, 2026, following the IPO completed during the quarter.
What was the Basic Earnings per Share (EPS) for Symbiotec Pharmalab in Q2 FY27?
The Basic Earnings per Share (EPS) for Symbiotec Pharmalab for Q2 FY27 was Rs. 8.20.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.